Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) Operating Expenses (2020 - 2026)

NeuroPace has reported Operating Expenses over the past 7 years, most recently at $23.6 million for Q1 2026.

  • For Q1 2026, Operating Expenses rose 5.01% year-over-year to $23.6 million; the TTM value through Mar 2026 reached $94.7 million, up 14.97%, while the annual FY2025 figure was $93.6 million, 15.85% up from the prior year.
  • Operating Expenses for Q1 2026 was $23.6 million at NeuroPace, up from $22.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $25.0 million in Q2 2025 and troughed at $18.0 million in Q1 2022.
  • A 5-year average of $20.4 million and a median of $19.8 million in 2023 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: surged 45.72% in 2022 and later decreased 0.35% in 2023.
  • Year by year, Operating Expenses stood at $18.7 million in 2022, then decreased by 0.35% to $18.6 million in 2023, then increased by 6.69% to $19.8 million in 2024, then increased by 12.62% to $22.3 million in 2025, then increased by 5.69% to $23.6 million in 2026.
  • Business Quant data shows Operating Expenses for NPCE at $23.6 million in Q1 2026, $22.3 million in Q4 2025, and $23.8 million in Q3 2025.